Ania M. Jastreboff, MD, PhD is a Professor of Medicine and Pediatrics at Yale School of Medicine. Dr. Jastreboff is an endocrinologist, clinically active physician-scientist and international thought leader in the scientific development and clinical application of novel anti-obesity pharmacotherapeutics revolutionizing obesity treatment. As director of the Yale Obesity Research Center (Y-Weight), she is leading and shaping pivotal landmark studies of dual- and triple-receptor hormone agonists and NIH-funded studies investigating the physiology of obesity. She has served as lead investigator and author for trials investigating novel nutrient-stimulated hormone (NuSH)-based therapies for obesity including dual hormone receptor agonist, tirzepatide, a GIP/GLP-1 receptor agonist (Jastreboff, et al., NEJM, 2022 & NEJM, 2024) and triple hormone receptor agonist retatrutide, a GIP/GLP-1/Glucagon receptor agonist (Jastreboff, et al., NEJM, 2023). Trained in both adult endocrinology and pediatric endocrinology, she serves on the Board of Governance for The Obesity Society, as a director on the American Board of Obesity Medicine, developing Obesity Clinical Practice Guidelines, and as co-director of the Yale Center for Weight Management, where she sees patients and teach trainees. She is a highly sought after speaker, teaching internationally, nationally, and locally. She is also a compassionate advocate for patients with obesity, from grass-roots patient groups to interviews with Ms. Oprah Winfrey.